Richard J Vickers Selected Research

ridinilazole

1/2020	Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids.
1/2017	Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
8/2016	Ridinilazole: a novel therapy for Clostridium difficile infection.
1/2015	SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard J Vickers Research Topics

Disease

4	Clostridium Infections 01/2020 - 01/2015
4	Infections 01/2018 - 01/2015
1	Dysbiosis 01/2020

Drug/Important Bio-Agent (IBA)

4	ridinilazoleIBA 01/2020 - 01/2015
3	Vancomycin FDA LinkGeneric 01/2018 - 01/2015
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 08/2016
1	Bile Acids and Salts (Bile Acids)IBA 01/2020
1	Pharmaceutical PreparationsIBA 01/2017
1	FidaxomicinIBA 01/2015

Therapy/Procedure

3	Therapeutics 01/2020 - 01/2015